PAM
HRTX icon

Panagora Asset Management’s Heron Therapeutics HRTX Stock Holding History

Panagora Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$770K Buy
962,505
+522,253
+119% +$605K ﹤0.01% 768
2025
Q4 		$572K Buy
+440,252
New +$544K ﹤0.01% 842
2024
Q3 		– Sell
-562,228
Closed -$1.97M – 1226
2024
Q2 		$1.97M Buy
562,228
+186,802
+50% +$574K 0.01% 525
2024
Q1 		$1.04M Buy
375,426
+236,313
+170% +$594K 0.01% 788
2023
Q4 		$236K Buy
+139,113
New +$153K ﹤0.01% 1143
2023
Q1 		– Sell
-480,788
Closed -$1.2M – 1488
2022
Q4 		$1.2M Buy
480,788
+455,889
+1,831% +$1.47M 0.01% 814
2022
Q3 		$105K Buy
24,899
+8,011
+47% +$31.3K ﹤0.01% 1402
2022
Q2 		$47K Buy
16,888
+3,341
+25% +$13.4K ﹤0.01% 1452
2022
Q1 		$77K Sell
13,547
-78,133
-85% -$572K ﹤0.01% 1504
2021
Q4 		$837K Sell
91,680
-404,603
-82% -$4.13M ﹤0.01% 1002
2021
Q3 		$5.3M Sell
496,283
-133
-0% -$1.62K 0.03% 413
2021
Q2 		$7.7M Sell
496,416
-11,170
-2% -$178K 0.04% 356
2021
Q1 		$8.23M Sell
507,586
-9,266
-2% -$165K 0.05% 355
2020
Q4 		$10.9M Sell
516,852
-10,711
-2% -$186K 0.06% 261
2020
Q3 		$7.82M Buy
527,563
+99,295
+23% +$1.55M 0.05% 287
2020
Q2 		$6.3M Buy
428,268
+127,504
+42% +$2.09M 0.04% 342
2020
Q1 		$3.53M Buy
300,764
+210,384
+233% +$3.95M 0.03% 438
2019
Q4 		$2.12M Sell
90,380
-105,452
-54% -$2.33M 0.01% 765
2019
Q3 		$3.62M Sell
195,832
-454,176
-70% -$8.36M 0.02% 548
2019
Q2 		$12.1M Buy
650,008
+83,352
+15% +$1.66M 0.05% 305
2019
Q1 		$13.8M Buy
566,656
+95,784
+20% +$2.51M 0.06% 286
2018
Q4 		$12.2M Buy
470,872
+94,253
+25% +$2.59M 0.06% 274
2018
Q3 		$11.9M Buy
376,619
+14,143
+4% +$527K 0.04% 326
2018
Q2 		$14.1M Sell
362,476
-25,027
-6% -$797K 0.06% 283
2018
Q1 		$10.7M Buy
387,503
+28,348
+8% +$643K 0.04% 350
2017
Q4 		$6.5M Sell
359,155
-11,604
-3% -$189K 0.02% 480
2017
Q3 		$5.99M Sell
370,759
-25,497
-6% -$400K 0.02% 520
2017
Q2 		$5.49M Sell
396,256
-45,919
-10% -$665K 0.02% 549
2017
Q1 		$6.63M Buy
442,175
+168,202
+61% +$2.33M 0.03% 515
2016
Q4 		$3.59M Buy
273,973
+72,316
+36% +$1.13M 0.02% 662
2016
Q3 		$3.48M Sell
201,657
-59,641
-23% -$1.11M 0.02% 676
2016
Q2 		$4.72M Buy
261,298
+15,906
+6% +$311K 0.02% 575
2016
Q1 		$4.66M Buy
245,392
+116,461
+90% +$2.3M 0.02% 597
2015
Q4 		$3.44M Buy
128,931
+43,072
+50% +$1.15M 0.02% 642
2015
Q3 		$2.1M Buy
85,859
+11,342
+15% +$378K 0.01% 751
2015
Q2 		$2.32M Buy
74,517
+66,907
+879% +$1.26M 0.01% 756
2015
Q1 		$111K Buy
+7,610
New +$85.8K ﹤0.01% 1913

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Panagora Asset Management's HRTX Position: Q1 2026 in Review

Panagora Asset Management increased its Heron Therapeutics (HRTX) stake by 119% in Q1 2026, buying an estimated $605K and bringing the position to 962,505 shares worth $770K. The position accounts for ﹤0.01% of the portfolio, ranked #768.

Panagora Asset Management first reported a position in HRTX in Q1 2015 and has held it in 37 quarters since. The position peaked at $14.1M in Q2 2018. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Panagora Asset Management held 962,505 shares of Heron Therapeutics worth $770K as of Q1 2026.
  • Panagora Asset Management bought 522,253 Heron Therapeutics shares in Q1 2026, an estimated $605K.
  • Heron Therapeutics made up ﹤0.01% of Panagora Asset Management's portfolio in Q1 2026, its #768 holding.
  • Panagora Asset Management first reported a position in Heron Therapeutics in Q1 2015 and has held it in 37 quarters since.
  • Panagora Asset Management's Heron Therapeutics position peaked at $14.1M in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Panagora Asset Management's 13F filing for Q1 2026, filed 14 May 2026.